Compare NVR & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVR | PODD |
|---|---|---|
| Founded | 1980 | 2000 |
| Country | United States | United States |
| Employees | N/A | 5400 |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9B | 12.7B |
| IPO Year | 1995 | 2007 |
| Metric | NVR | PODD |
|---|---|---|
| Price | $6,304.74 | $170.91 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 21 |
| Target Price | ★ $7,157.80 | $341.48 |
| AVG Volume (30 Days) | 14.6K | ★ 902.9K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 436.55 | 3.48 |
| Revenue | ★ $10,323,959,000.00 | $2,708,100,000.00 |
| Revenue This Year | N/A | $24.55 |
| Revenue Next Year | $6.60 | $19.18 |
| P/E Ratio | ★ $14.21 | $46.25 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $6,195.17 | $158.35 |
| 52 Week High | $8,618.28 | $354.88 |
| Indicator | NVR | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 38.00 | 26.93 |
| Support Level | $6,301.03 | N/A |
| Resistance Level | $7,778.36 | $205.95 |
| Average True Range (ATR) | 191.50 | 7.04 |
| MACD | -48.94 | -1.91 |
| Stochastic Oscillator | 9.85 | 26.32 |
NVR Inc is engaged in the construction and sale of residential properties, including single-family detached homes, townhomes, and condominium buildings, all of which are built on a pre-sold basis. Additionally, the company provides related services through its mortgage banking and title services businesses. Its business segments are Homebuilding and Mortgage Banking. Its geographical segments include the Mid Atlantic, the North East, the Mid East, and the South East regions of America. The majority of the company's revenue is derived from the Homebuilding Mid Atlantic segment, which includes homebuilding operations that construct and sell single-family detached homes, townhomes and condominiums in Maryland, Virginia, West Virginia, Delaware and Washington, D.C. regions.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.